GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (FRA:8LY) » Definitions » Net Margin %

OncoZenge AB (FRA:8LY) Net Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. OncoZenge AB's Net Income for the three months ended in Dec. 2024 was €-0.22 Mil. OncoZenge AB's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, OncoZenge AB's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for OncoZenge AB's Net Margin % or its related term are showing as below:


FRA:8LY's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -119.77
* Ranked among companies with meaningful Net Margin % only.

OncoZenge AB Net Margin % Historical Data

The historical data trend for OncoZenge AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Net Margin % Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
- - - - -

OncoZenge AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoZenge AB's Net Margin %

For the Biotechnology subindustry, OncoZenge AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoZenge AB's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's Net Margin % falls into.


;
;

OncoZenge AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

OncoZenge AB's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-0.755/0
= %

OncoZenge AB's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-0.217/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoZenge AB  (FRA:8LY) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


OncoZenge AB Net Margin % Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoZenge AB Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines